IL131025A0 - Treatment of autoimmune disease using tolerization in combination with methotrexate - Google Patents
Treatment of autoimmune disease using tolerization in combination with methotrexateInfo
- Publication number
- IL131025A0 IL131025A0 IL13102598A IL13102598A IL131025A0 IL 131025 A0 IL131025 A0 IL 131025A0 IL 13102598 A IL13102598 A IL 13102598A IL 13102598 A IL13102598 A IL 13102598A IL 131025 A0 IL131025 A0 IL 131025A0
- Authority
- IL
- Israel
- Prior art keywords
- tolerization
- methotrexate
- treatment
- combination
- autoimmune disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
- B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
- B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
- B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
- B41J2/01—Ink jet
- B41J2/21—Ink jet for multi-colour printing
- B41J2/2107—Ink jet for multi-colour printing characterised by the ink properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
- G06K2215/0082—Architecture adapted for a particular function
- G06K2215/0094—Colour printing
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
- G06K2215/0082—Architecture adapted for a particular function
- G06K2215/0097—Printing on special media, e.g. labels, envelopes
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3672297P | 1997-01-24 | 1997-01-24 | |
PCT/US1998/001648 WO1998032451A1 (en) | 1997-01-24 | 1998-01-26 | Treatment of autoimmune disease using tolerization in combination with methotrexate |
Publications (1)
Publication Number | Publication Date |
---|---|
IL131025A0 true IL131025A0 (en) | 2001-01-28 |
Family
ID=21890248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13102598A IL131025A0 (en) | 1997-01-24 | 1998-01-26 | Treatment of autoimmune disease using tolerization in combination with methotrexate |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0994717A4 (ja) |
JP (1) | JP2001511134A (ja) |
KR (1) | KR20000070460A (ja) |
AU (1) | AU6648898A (ja) |
BR (1) | BR9807112A (ja) |
CA (1) | CA2278152A1 (ja) |
HU (1) | HUP0001960A2 (ja) |
IL (1) | IL131025A0 (ja) |
NO (1) | NO993600L (ja) |
WO (1) | WO1998032451A1 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE409057T1 (de) | 2002-02-11 | 2008-10-15 | Antares Pharma Inc | Intradermales injektionsgerät |
WO2006079064A1 (en) | 2005-01-24 | 2006-07-27 | Antares Pharma, Inc. | Prefilled needle assisted jet injector |
GB0523576D0 (en) * | 2005-11-18 | 2005-12-28 | Theradeas Ltd | Drug composition and its use in therapy |
US9144648B2 (en) | 2006-05-03 | 2015-09-29 | Antares Pharma, Inc. | Injector with adjustable dosing |
US8251947B2 (en) | 2006-05-03 | 2012-08-28 | Antares Pharma, Inc. | Two-stage reconstituting injector |
JP5731829B2 (ja) | 2008-03-10 | 2015-06-10 | アンタレス・ファーマ・インコーポレーテッド | 注射器安全装置 |
WO2010017285A2 (en) | 2008-08-05 | 2010-02-11 | Antares Pharma, Inc. | Multiple dosage injector |
EP2408493A1 (en) | 2009-03-20 | 2012-01-25 | Antares Pharma, Inc. | Hazardous agent injection system |
KR101801864B1 (ko) | 2010-06-16 | 2017-11-27 | 인플래머토리 리스폰스 리서치, 아이엔씨. | 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도 |
US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
US8496619B2 (en) | 2011-07-15 | 2013-07-30 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
DK2822618T3 (da) | 2012-03-06 | 2024-01-22 | Antares Pharma Inc | Forfyldt nål med brudkraftfunktion |
EP2833944A4 (en) | 2012-04-06 | 2016-05-25 | Antares Pharma Inc | ADMINISTRATION OF TESTOSTERONE COMPOSITIONS BY NEEDLE-SUPPORTED NOZZLE INJECTION |
WO2013169804A1 (en) | 2012-05-07 | 2013-11-14 | Antares Pharma, Inc. | Needle assisted jet injection device having reduced trigger force |
FI3659647T3 (fi) | 2013-02-11 | 2024-03-28 | Antares Pharma Inc | Neula-avusteinen suihkuinjektiolaite, jolla on pienennetty liipaisinvoima |
ES2742046T3 (es) | 2013-03-11 | 2020-02-12 | Antares Pharma Inc | Inyector de dosis con sistema de piñón |
WO2014165136A1 (en) | 2013-03-12 | 2014-10-09 | Antares Pharma, Inc. | Constant volume prefilled syringes and kits thereof |
KR20160125283A (ko) | 2013-03-13 | 2016-10-31 | 인플래머토리 리스폰스 리서치, 아이엔씨. | 레보세티리진 및 몬테루카스트의 혈관염의 치료 용도 |
ES2745041T3 (es) * | 2013-03-13 | 2020-02-27 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunitarios |
EP3308835B1 (en) | 2013-03-13 | 2020-01-01 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of traumatic injury |
JP2017526728A (ja) | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571500A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases through administration by inhalation of autoantigens |
US5571499A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
AU632991B2 (en) * | 1987-06-24 | 1993-01-21 | Autoimmune, Inc. | Treatment of autoimmune diseases by oral administration of autoantigens |
AU650065B2 (en) * | 1990-09-06 | 1994-06-09 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur | Inhibitor of lymphocyte response and immune-related disease |
ATE228373T1 (de) * | 1992-02-28 | 2002-12-15 | Autoimmune Inc | Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung |
WO1996040235A1 (en) * | 1995-06-07 | 1996-12-19 | Nexstar Pharmaceuticals, Inc. | Method to use superantigens to target subpopulations of t cells |
DE69627855T2 (de) * | 1995-06-13 | 2004-03-11 | Nippon Meat Packers, Inc. | Orales mittel gegen rheumatische arthritis und funktionelles nahrungsmittel |
-
1998
- 1998-01-26 KR KR1019997006698A patent/KR20000070460A/ko not_active Application Discontinuation
- 1998-01-26 CA CA002278152A patent/CA2278152A1/en not_active Abandoned
- 1998-01-26 AU AU66488/98A patent/AU6648898A/en not_active Abandoned
- 1998-01-26 HU HU0001960A patent/HUP0001960A2/hu unknown
- 1998-01-26 EP EP98908452A patent/EP0994717A4/en not_active Withdrawn
- 1998-01-26 JP JP53225298A patent/JP2001511134A/ja active Pending
- 1998-01-26 BR BR9807112-2A patent/BR9807112A/pt not_active Application Discontinuation
- 1998-01-26 IL IL13102598A patent/IL131025A0/xx unknown
- 1998-01-26 WO PCT/US1998/001648 patent/WO1998032451A1/en not_active Application Discontinuation
-
1999
- 1999-07-23 NO NO993600A patent/NO993600L/no unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0001960A2 (hu) | 2000-10-28 |
NO993600L (no) | 1999-09-23 |
CA2278152A1 (en) | 1998-07-30 |
JP2001511134A (ja) | 2001-08-07 |
EP0994717A1 (en) | 2000-04-26 |
EP0994717A4 (en) | 2000-07-26 |
AU6648898A (en) | 1998-08-18 |
NO993600D0 (no) | 1999-07-23 |
WO1998032451A1 (en) | 1998-07-30 |
BR9807112A (pt) | 2001-09-18 |
KR20000070460A (ko) | 2000-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL131025A0 (en) | Treatment of autoimmune disease using tolerization in combination with methotrexate | |
EP1024701A4 (en) | METHOD AND MEANS FOR TREATING AUTOIMMUNE DISEASES USING HEAT SHOCK PROTEINS | |
ZA9710339B (en) | Xanthines and their therapeutic use | |
HUP0004439A3 (en) | 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders | |
ZA983452B (en) | Substituted pyrrolopyridines useful in the treatment of inflammatory diseases. | |
IL159785A0 (en) | Thienopyrimidinediones and their use in the modulation of autoimmune disease | |
EP0924983A4 (en) | S (-) - TOLTERODINE FOR THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS | |
EP0966386A4 (en) | HUMAN TRACTION VEHICLE | |
HUP0102142A3 (en) | Use of cyclosporins in the treatment of inflammatory autoimmune diseases | |
HUP0001276A3 (en) | Illuminating body for swimming pools and similar | |
HK1026096A1 (en) | Novel triptolide derivatives useful in the treatment of autoimmune diseases | |
IL113303A0 (en) | Treatment of autoimmune disease using oral tolerization and/or type I interferon | |
HU9602751D0 (en) | Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines | |
HUP9900147A3 (en) | Therapeutic agents and autoimmune diseases | |
HK1025954A1 (en) | Triptolide derivatives useful in the treatment of autoimmune diseases | |
EP0797440A4 (en) | TREATING AUTOIMMUNE DISEASES WITH THE AID OF 2-AMINOPURINE DERIVATIVES | |
GB9621825D0 (en) | Microparticles and their use as therapeutic vehicles | |
GB9705200D0 (en) | Well treatment with particles | |
IL129460A0 (en) | Use of lofexidine in the treatment of behavioral disorders | |
EP1073459A4 (en) | COMPOSITIONS AND METHODS OF TOLERATING IN IMMUNOMOPLEX-MEDIATED ILLNESS | |
HUP9902802A3 (en) | Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders | |
AU7262800A (en) | Diagnostic and therapeutic methods in autoimmune disease | |
EP1020517A4 (en) | A HUMAN CHONDROCYTE GENE | |
IL132845A0 (en) | Non-myeloablative tolerogenic treatment | |
GB9706857D0 (en) | Car boot seat and table |